Mutations or deletions of SMAD4 are observed in 50% of pancreatic ductal adenocarcinoma (PDAC) cases1 and its deletion in the background of oncogenic KrasG12D expression in mice has been shown to promote pancreatic tumor development and metastasis17. This evidence concerns the gene SMAD4 and pancreatic neoplasm.